LIVTENCITY (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
LIVTENCITY
Date registered
Evaluation commenced
Decision date
Approval time
155 (255 working days)
Active ingredients
maribavir
Registration type
NCE/NBE
Indication
LIVTENCITY (film coated tablet) is indicated for the treatment of adults with post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies (see 4.3 CONTRAINDICATIONS and, 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).